Distinctive syringe design to ease insertion

Ready to use. No assembly needed.

UROSAFETIP®: Rounded, smooth, elongated tip1

JELIDO® comes in the prefilled FARCO®* syringe, designed to help minimize epithelial damage. The innovative UROSAFETIP® design helps reduce the risk of injury and supports patient comfort.1


Get step-by-step instructions on how to administer JELIDO®

Visual of the FARCO®* prefilled syringe

FARCO®* prefilled syringe

Broad flanges help prevent slipping

Rounded, smooth, elongated tip

JELIDO® is well tolerated and effective and may help minimize the risk of urethral mucosal injury.2,3

Minimal bubbles1

Reduced bubble formation during instillation provides uniform coating and does not impair vision during endoscopic procedures.


In the in vitro flow assessment, gel was dispensed from the FARCO®* syringe into glass tubes over a 5-second period†,‡,§

Image showing bubble formation during FARCO®* gel delivery

FARCO®* SYRINGE

  • Section 1
  • Section 2
  • Section 3
  • Section 4

Application directionGel direction

  • Bubble formation is minimized
  • Bubble formation can occur towards the end of the instillation process

Bubble formation was not evaluated quantitatively. Clinical significance is unknown.

Complete delivery / minimal residual gel1

Urethra should be fully coated for optimal preparation and for carrying out the transurethral procedure.

The fill volume of the FARCO®* syringe can be instilled completely

Got questions about JELIDO®?

Filling volume of the FARCO®* syringe compared to male urethra

Average volume of the male urethra is 10.6 mL

11 mL

MALE URETHRA

FARCO®* SYRINGE

INSTILLAGEL

For an antiseptic lubricant gel option for catheterization

Learn more

JELIDO® (lidocaine hydrochloride jelly) is indicated for:2

  • Surface anaesthesia and lubrication for:
    • The male and female urethra during cystoscopy, catheterization, exploration by sound, and other endourethral operations;
    • Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy;
    • Proctoscopy and rectoscopy;
    • Tracheal intubation.
  • Symptomatic treatment of pain in connection with cystitis and urethritis

for additional safety information and for a link to the Product Monograph, which discusses:2

  • Contraindications in patients with: a hypersensitivity to this drug or any ingredient in the formulation; a known history of hypersensitivity to amide-type local anaesthetics or other formulation components; congenital or idiopathic methemoglobinemia; a need for treatment with methemoglobin-inducing agents (e.g., sulfonamides) in infants ≤ 12 months of age; or, glucose-6-phosphate dehydrogenase deficiency.
  • Most serious warnings and precautions regarding: adherence to the recommended dosage; and use in children and infants (< 3 months of age)
  • Other relevant warnings and precautions regarding: use of the lowest effective dose; avoiding contact with eyes; familial malignant hyperthermia; increased plasma concentrations in patients under general anaesthesia; use in unparalyzed patients; endotracheal tube lubrication; risk of aspiration; unintentional biting trauma; impairment of locomotion or alertness; caution when driving and operating machinery; and use in patients with porphyria. Use with caution in patients with: sepsis; traumatized mucosa at the application site; epilepsy; severe shock; bradycardia; impaired cardiovascular function; hepatic disease or impaired renal function; or known drug sensitivities. Reduced doses should be given in debilitated patients, acutely ill patients, and patients with sepsis. Care should be taken during early pregnancy.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

INSTILLAGEL® (lidocaine and chlorhexidine gel) is indicated for surface anaesthesia, lubrication, and antisepsis for:4

  • The male and female urethra during cystoscopy
  • Catheterization
  • Exploration by sound and other endourethral operations

Consult the Prescribing Information for contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Prescribing Information is also available by calling 1-888-550-6060.

†The assays were performed using INSTILLAGEL® in the prefilled FARCO®* syringe with the UROSAFETIP®. JELIDO® is supplied in the same prefilled FARCO®* syringe with the UROSAFETIP®.
‡Internal diameter 5 mm.
§The syringe tests were performed in horizontal position.

References: 1. Data on file. PENDOPHARM®, Division of Pharmascience Inc. 2. JELIDO® Product Monograph. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2026. 3. Sperling H, Lümmen G, Rübben H. The use of lubricants in urology. Indications and results. Urologe. [A] 2005;44(6):662-666. 4. INSTILLAGEL® Prescribing Information. PENDOPHARM®, Division of Pharmascience Inc. February 19, 2025.

PENDOPHARM

JELIDO and UROSAFETIP are registered trademarks of Finchley Research & Development Inc., used under license. INSTILLAGEL is a registered trademark of FARCO-PHARMA GmbH, used under license. PENDOPHARM and its logo are registered trademarks of Finchley Research & Development Inc., used under license.

*Registered trademarks are the property of their respective owners.

© 2026 PENDOPHARM®. All rights reserved.

Publication date: 29-10-2026

Contact us

For any questions about our products or further information about our company, please do not hesitate to contact us.

JELIDO® and INSTILLAGEL® are available at select specialty pharmacies and by special order at most pharmacy outlets.

6111 Royalmount AvenueMontreal (Quebec)H4P 2T4, CanadaTelephone+1 (514) 340-5045Fax+1 (866) 926-7654 or +1 (514) 733-9684

MED INFO

Toll-free Telephone: +1 (888) 550-6060
Fax: +1 (514) 340-0164
E-mail: medinfo@pharmascience.com

PHARMACOVIGILANCE:

By Telephone: +1 (888) 550-6060
By Fax: +1 (866) 551-1939
By E-mail: adr@pharmascience.com

For Medical and Scientific Information Services, Adverse Event Report, and Customer Service, please visit our website at https://pendopharm.com/contact/.

JELIDO® important safety information

Indications and clinical use:

JELIDO® (lidocaine hydrochloride jelly) is indicated for:

  • Surface anaesthesia and lubrication for:
    • The male and female urethra during cystoscopy, catheterization, exploration by sound, and other endourethral operations
    • Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy
    • Proctoscopy and rectoscopy
    • Tracheal intubation
  • Symptomatic treatment of pain in connection with cystitis and urethritis

Pediatrics (2–18 years of age): Children should be given reduced doses commensurate with their age, weight, and physical condition.

Pediatrics (< 2 years of age): Lidocaine should be used with caution in children younger than two years of age as there are insufficient data to support the safety and efficacy of this product in this patient population at this time.

Geriatrics (> 65 years of age): Elderly patients should be given reduced doses commensurate with their age and physical condition.

Contraindications:

  • Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or any component of the container
  • Patients with a known history of hypersensitivity to local anaesthetics of the amide type or to other components in the formulation
  • Patients with congenital or idiopathic methemoglobinemia
  • Infants ≤ 12 months of age who require treatment with methemoglobin-inducing agents (e.g., sulfonamides)
  • Patients with glucose-6-phosphate dehydrogenase deficiency, which makes them more susceptible to drug-induced methemoglobinemia

Most serious warnings and precautions:

  • PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE: EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS OF LIDOCAINE OR ITS METABOLITES AND SERIOUS, AS WELL AS LIFE-THREATENING, ADVERSE EFFECTS, including methemoglobinemia.
  • Use in children and infants (< 3 months): Ensure the caregiver understands to limit the dose and area of application and to prevent accidental ingestion. Children should be closely observed during and after use of lidocaine as they are at greater risk than adults for serious adverse events (e.g., methemoglobinemia).

Other relevant warnings and precautions:

  • Lowest effective dose should be used
  • Avoid contact with eyes
  • Potential triggering agent for familial malignant hyperthermia
  • In patients under general anaesthesia who are paralyzed, higher plasma concentrations may occur than in spontaneously breathing patients
    • Unparalyzed patients are more likely to swallow a large proportion of the dose, which then undergoes considerable first-pass hepatic metabolism following absorption from the gut
  • Endotracheal tube lubrication
    • Avoid introduction of the jelly into the lumen of the tube
    • Do not use to lubricate the endotracheal stylettes
  • Topical anaesthetics used in the mouth may enhance the danger of aspiration
  • Numbness of the tongue or buccal region may enhance unintentional biting trauma
  • May temporarily impair locomotion or alertness
  • Use with caution in patients with:
    • Sepsis
    • Traumatized mucosa at the area of application
    • Epilepsy
    • Severe shock
    • Bradycardia
    • Impaired cardiovascular function
    • Hepatic disease or impaired renal function
    • Known drug sensitivities
  • Exercise caution when driving and operating machinery
  • Exercise caution with use in all porphyric patients
  • Reduced doses should be given in debilitated patients, acutely ill patients, and patients with sepsis
  • Care should be taken during early pregnancy

For more information:

Consult the Product Monograph for important information relating to adverse events, drug interactions, and dosing that has not been discussed in this piece. The Product Monograph is also available by calling 1-888-550-6060.